Caribou Biosciences, Inc. reported financial results for the first quarter of 2026.
“reported financial results for the first quarter of 2026 and provided a business update.”
Caribou Biosciences, Inc. — fact timeline
Source-grounded facts extracted from Caribou Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sriram Ryali was appointed as Chief Financial Officer at Caribou Biosciences, Inc..
“On January 2, 2025, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), announced the appointment of Sriram Ryali, age 44, to the position of Chief Financial Officer (“CFO”) of the Company, effective as of January 2, 2025 (the “Start Date”).”
Ryan Fischesser was appointed as Interim Principal Financial Officer and Interim Principal Accounting Officer at Caribou Biosciences, Inc..
“On September 23, 2024, Caribou Biosciences, Inc. (the “Company”) designated Ryan Fischesser, the Company’s current Vice President of Finance and Controller, as the Company’s interim principal financial officer and interim principal accounting officer, effective as of 5:00 p.m. Pacific time on September 27, 2024.”
Jason O'Byrne resigned as Chief Financial Officer at Caribou Biosciences, Inc..
“Mr. O’Byrne serves as the Company’s principal financial officer and principal accounting officer through September 27, 2024, his final day with the Company.”
Ryan Fischesser was appointed as principal accounting officer at Caribou Biosciences, Inc..
“The Company intends to appoint Ryan Fischesser, the Company’s current Vice President of Finance and Controller, to assume the role of the Company’s principal accounting officer, effective as of the close of business on September 27, 2024.”
Jason O'Byrne resigned as Chief Financial Officer at Caribou Biosciences, Inc..
“On September 1, 2024, Jason O’Byrne, the Chief Financial Officer of Caribou Biosciences, Inc. (the “Company”), informed the Company of his intent to resign from his position, effective September 27, 2024, to pursue another opportunity.”
Caribou Biosciences, Inc. reported the quarter ended March 31, 2024 results: revenue $2.4 million.
“Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $2.4 million for the three months ended March 31, 2024, compared to $3.5 million for the same period in 2023.”
Caribou Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“On March 11, 2024, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2023 and providing a business update.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.